Ponatinib (Iclusig®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015000585
English
Authors' recommendations:
Ponatinib (Iclusig®) is recommended as an option for use within NHS Wales for the treatment of adult patients with:
• Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation;
• Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/1163
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Antineoplastic Agents
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia
- Leukemia, Lymphoid
- Philadelphia Chromosome
- Protein Kinase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.